Valeant Pharmaceuticals International Inc. (NYSE:VRX) shares were down 1.3% during mid-day trading on Monday . The company traded as low as $30.00 and last traded at $30.43, with a volume of 11,238,112 shares trading hands. The stock had previously closed at $30.83.

VRX has been the topic of several recent analyst reports. Mizuho raised Valeant Pharmaceuticals International from an “underperform” rating to a “neutral” rating and set a $25.00 target price on the stock in a research note on Thursday, August 11th. Rodman & Renshaw cut their target price on Valeant Pharmaceuticals International from $105.00 to $102.00 and set a “buy” rating on the stock in a research note on Tuesday, May 3rd. BMO Capital Markets reissued a “market perform” rating and issued a $44.00 target price (down from $66.00) on shares of Valeant Pharmaceuticals International in a research note on Thursday, May 5th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $33.00 target price (down from $58.00) on shares of Valeant Pharmaceuticals International in a research note on Friday, June 3rd. Finally, TD Securities reissued a “hold” rating and issued a $38.00 target price on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 17th. Six equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Valeant Pharmaceuticals International presently has an average rating of “Hold” and a consensus target price of $60.32.

The firm’s 50-day moving average price is $25.08 and its 200-day moving average price is $35.73. The stock’s market cap is $10.51 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last posted its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.48 by $0.08. The firm had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.47 billion. During the same quarter in the previous year, the business posted $2.14 earnings per share. The firm’s revenue for the quarter was down 11.4% on a year-over-year basis. On average, equities analysts expect that Valeant Pharmaceuticals International Inc. will post $6.54 earnings per share for the current year.

In related news, Director Argeris N. Karabelas purchased 4,000 shares of the stock in a transaction dated Thursday, August 11th. The shares were acquired at an average cost of $24.65 per share, with a total value of $98,600.00. Following the purchase, the director now directly owns 20,726 shares in the company, valued at approximately $510,895.90. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Joseph C. Papa purchased 202,000 shares of the stock in a transaction dated Friday, June 10th. The shares were bought at an average cost of $24.48 per share, for a total transaction of $4,944,960.00. Following the completion of the purchase, the chief executive officer now owns 2,442,199 shares in the company, valued at $59,785,031.52. The disclosure for this purchase can be found here.

A hedge fund recently bought a new stake in Valeant Pharmaceuticals International stock. State of New Jersey Common Pension Fund D purchased a new position in Valeant Pharmaceuticals International Inc. (NYSE:VRX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 20,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,033,000.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.